Get the Stockscreener App
77.95
1.23%
0.93
After Hours:
77.67
-0.28
-0.36%
Overview
News
Price History
Option Chain
Financials
Why CVS Down?
Discussions
Forecast
Stock Split
Dividend History
Cvs Health Corp stock is traded at $77.95, with a volume of 6.61M.
It is up +1.23% in the last 24 hours and down -2.98% over the past month.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
See More
Previous Close:
$77.02
Open:
$77.51
24h Volume:
6.61M
Relative Volume:
0.80
Market Cap:
$99.12B
Revenue:
$402.11B
Net Income/Loss:
$1.73B
P/E Ratio:
56.53
EPS:
1.3789
Net Cash Flow:
$7.81B
1W Performance:
+2.14%
1M Performance:
-2.98%
6M Performance:
+19.01%
1Y Performance:
+23.32%
1-Day Range:
$77.08
$79.06
1-Week Range:
$73.00
$79.06
52-Week Range:
$58.35
$85.15
Cvs Health Corp Stock (CVS) Company Profile
Name
Cvs Health Corp
Sector
Industry
Phone
(401) 765-1500
Address
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, CI, ELV, HUM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
77.91 | 97.99B | 402.11B | 1.73B | 7.81B | 1.3789 |
|
UNH
Unitedhealth Group Inc
|
284.49 | 252.65B | 447.57B | 12.81B | 16.08B | 13.19 |
|
CI
Cigna Group
|
287.49 | 77.65B | 216.66B | 6.25B | 7.44B | 22.19 |
|
ELV
Elevance Health Inc
|
336.04 | 72.89B | 199.13B | 5.66B | 3.17B | 25.11 |
|
HUM
Humana Inc
|
179.00 | 21.10B | 126.36B | 1.30B | 1.55B | 10.67 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Goldman | Buy |
| Aug-18-25 | Upgrade | UBS | Neutral → Buy |
| Aug-14-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-12-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-30-25 | Upgrade | Edward Jones | Hold → Buy |
| Dec-03-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-18-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-04-24 | Upgrade | TD Cowen | Hold → Buy |
| May-30-24 | Initiated | Robert W. Baird | Neutral |
| May-07-24 | Downgrade | TD Cowen | Buy → Hold |
| May-02-24 | Downgrade | UBS | Buy → Neutral |
| May-01-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-01-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Dec-22-23 | Initiated | HSBC Securities | Buy |
| Sep-19-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-12-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-18-23 | Downgrade | Edward Jones | Buy → Hold |
| May-26-23 | Initiated | Piper Sandler | Overweight |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Resumed | Morgan Stanley | Overweight |
| Jun-17-22 | Initiated | Loop Capital | Buy |
| May-27-22 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-29-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-14-21 | Initiated | Goldman | Buy |
| Dec-01-21 | Initiated | Seaport Research Partners | Buy |
| May-19-21 | Initiated | Wells Fargo | Equal Weight |
| Mar-17-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-08-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-17-20 | Initiated | Piper Sandler | Overweight |
| Jul-01-20 | Initiated | SVB Leerink | Mkt Perform |
| May-14-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-27-19 | Resumed | RBC Capital Mkts | Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Buy |
| Jun-05-19 | Upgrade | Standpoint Research | Hold → Buy |
| Apr-29-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Apr-15-19 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-10-19 | Reiterated | BofA/Merrill | Buy |
| Mar-13-19 | Initiated | Bernstein | Outperform |
| Feb-20-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-18-18 | Initiated | Barclays | Overweight |
| Nov-29-18 | Resumed | Goldman | Neutral |
| Nov-28-18 | Initiated | Evercore ISI | Outperform |
| Oct-26-18 | Resumed | Wolfe Research | Peer Perform |
| Jul-09-18 | Upgrade | Citigroup | Neutral → Buy |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-13-18 | Reiterated | Citigroup | Neutral |
View All
Cvs Health Corp Stock (CVS) Latest News
Big Health Raises $23.7M from .406 Ventures, AlleyCorp, CVS Ventures, Blue Venture Fund - Behavioral Health Business
Analysts See Multiple Growth Levers For CVS In 2026 - Benzinga
Analysts See Multiple Growth Levers For CVS Health In 2026 - Benzinga
Is CVS’s Reaffirmed 2026 EPS Guidance Amid Medicare Advantage Uncertainty Altering The Investment Case For CVS Health (CVS)? - Yahoo Finance
Humana’s profit outlook adds to health insurance gloom - Modern Healthcare News
CVS Q4 Deep Dive: Pharmacy Turnaround and Regulatory Shifts Shape Outlook - Finviz
Mark Cuban Urges Trump To 'Put His Weight Behind' Josh Hawley, Elizabeth Warren's 'Break Up Big Medicine Act' - Benzinga
Decoding CVS Health Corp (CVS): A Strategic SWOT Insight - GuruFocus
CVS defends its scale as CEO Joyner aligns with Trump, blames pharma for high costs - The Business Journals
CVS Health Earnings Call: Cash, Growth And Cost Risks - TipRanks
CVS annual profit guidance misses Wall Street estimates - The Boston Globe
CVS Health Corp (CVS) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
CVS Reiterates 2026 Profit Outlook, Shares Slide 3.7% Despite Q4 Beat - TradingView
CVS year-end profit falls to $1.7B in 2025 - Providence Business News
What's Going On With CVS Health Stock Tuesday?CVS Health (NYSE:CVS) - Benzinga
House subpoenas CVS, Kaiser Permanente, others in ACA fraud probe - Modern Healthcare News
Gold Moves Lower; CVS Health Earnings Top Views - Benzinga
CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline - AlphaStreet News
CVS Health (CVS) Surpasses Expectations with Strong 2025 Performance - GuruFocus
CVS Health grapples with high costs, strategic reset - Modern Healthcare News
CVS Health Reports Strong Q4 2025 Earnings with Positive Outlook - Intellectia AI
CVS Earnings: 2026 Guidance Maintained After Strong Trends In Late 2025 - Morningstar
CVS Anticipates Medicare Margin Growth by 2026 - GuruFocus
CVS Faces Challenges with Proposed Rates Amid Rising Costs - GuruFocus
Jim Cramer on CVS: "I Think It's a Fascinating Time to Own the Stock" - Finviz
Jim Cramer on CVS: “I Think It’s a Fascinating Time to Own the Stock” - Insider Monkey
CVS Health Q4 2025 slides: Revenue jumps 8.2%, stock falls despite earnings beat - Investing.com
CVS Health posts strong Q4 revenue, raises full-year guidance - Proactive financial news
Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips By Investing.com - Investing.com India
CVS Keeps 2026 Forecast Steady Amid Tumult in Health Insurance - Bloomberg.com
Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips - Investing.com
CVS Health (CVS) Subpoenaed in ACA Fraud Investigation - GuruFocus
AI for investors - MLQ.ai
CVS Beats Q4 Revenue Estimates, Highlights Strategic Growth - GuruFocus
CVS Forecasts FY26 Operating Income in Billions - GuruFocus
CVS Maintains FY26 Effective Tax Rate Projection at 25.3% - GuruFocus
Republican-led House panel issues subpoenas to eight health insurers: Axios - CNBC
CVS Health Reports Q4 Beat but Maintains Full-Year Outlook - Intellectia AI
CVS Health (NYSE:CVS) Surprises With Q4 CY2025 Sales - Finviz
CVS Health Corp (NYSE:CVS) Beats Q4 Estimates but Shares Dip on Cautious Outlook - ChartMill
CVS Lowers Fiscal Year 2026 Cash Flow Outlook - GuruFocus
CVS Health (CVS) Surpasses Q4 Expectations with Strong Revenue G - GuruFocus
CVS Health beats Q4 expectations, cash flow guidance lowered - Investing.com
CVS Health Insiders Placed Bullish Bets Worth US$2.10m - Yahoo Finance
CVS Health beats quarterly profit expectations on pharmacy performance By Reuters - Investing.com
CVS HEALTH Corp SEC 10-K Report - TradingView
CVS Health Corp earnings beat by $0.09, revenue topped estimates - Investing.com
CVS Health keeps in place 2026 forecast, eyes topping it - Reuters
CVS Health beats quarterly profit expectations on pharmacy performance - Yahoo Finance
CVS posts Q4 sales of $105.7B, up 8.2% - breakingthenews.net
US House panel issues subpoenas to eight health insurers on alleged Obamacare fraud - Reuters
Cvs Health Corp Stock (CVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):